Welcome to our dedicated page for Repare Therapeutics SEC filings (Ticker: RPTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Repare Therapeutics’ SEC paperwork is packed with dense clinical data, synthetic lethality science, and cash-burn figures that can overwhelm even seasoned biotech analysts. If you have ever asked, “How do I read Repare Therapeutics’ annual report 10-K?” or hunted for “Repare Therapeutics insider trading Form 4 transactions,” you know the challenge.
Stock Titan solves this complexity. Our AI-powered summaries translate 300-page disclosures into clear takeaways, flagging trial milestones, collaboration revenue, and liquidity runways. Get real-time alerts the moment a “Repare Therapeutics Form 4 insider transactions real-time” filing hits EDGAR, review a “Repare Therapeutics quarterly earnings report 10-Q filing” with side-by-side metric trends, or skim the newest 8-K material events explained without scrolling through legal boilerplate.
Every document type is here—10-K, 10-Q, 8-K, S-8, DEF 14A proxy statements, plus
- “Repare Therapeutics executive stock transactions Form 4” for sentiment shifts
- “Repare Therapeutics earnings report filing analysis” to compare R&D expenses
- “Repare Therapeutics proxy statement executive compensation” to evaluate incentive alignment
Repare Therapeutics Inc. (RPTX) agreed to be acquired by non‑profit XenoTherapeutics, Inc. via a court‑approved plan of arrangement. Shareholders are expected to receive an estimated cash payment of about $1.82 per common share at closing, plus one non‑transferable contingent value right (CVR) per share that may pay additional cash based on future milestones under a CVR Agreement.
The company’s independent transaction committee and full board unanimously determined the arrangement is fair and in the best interests of shareholders and will recommend that shareholders vote in favor. The deal requires approval by at least 66⅔% of votes cast and a majority of minority shareholders, court approval under Québec law, and limits on dissenting shares, among other customary conditions. Officers and directors holding about 0.25% of outstanding shares have signed voting and support agreements in favor of the transaction.
Repare Therapeutics (RPTX) reported Q3 2025 results with net income of $3.3 million, led by $11.6 million of revenue from its Debiopharm license. Operating income was $1.1 million, supported by a $3.3 million gain from terminating a prior Debiopharm collaboration and $2.2 million of interest income. Basic and diluted EPS were $0.08.
Cash and cash equivalents were $72.8 million, with $39.8 million in marketable securities; total assets were $126.7 million and shareholders’ equity was $115.1 million. Year-to-date, the company recorded a net loss of $43.5 million and used $42.8 million in operating cash.
The company continued restructuring initiatives, incurring $1.8 million in Q3 and $8.5 million year-to-date. It also out‑licensed discovery platforms to DCx (9.99% equity stake and related rights) earlier in 2025.
Subsequent event: Repare signed a definitive agreement for acquisition by XenoTherapeutics. Holders will receive a cash payment per share based on cash at closing, plus one non‑transferable CVR per share; closing is subject to approvals and is expected in Q1 2026.
Repare Therapeutics reported a Regulation FD update announcing that the abstract from its Phase 1 LIONS trial of RP-1664 has been made available. The preliminary data in the abstract will be presented at the 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston. The abstract, titled “Preliminary safety and antitumor activity of RP-1664, a first-in-class PLK4 inhibitor, as monotherapy in advanced solid tumors with and without TRIM37 amplification,” is posted on the Company’s website under Science > Scientific References.
The Company noted that information on its website is not incorporated by reference into other filings unless specifically stated.
Repare Therapeutics (RPTX) – Q2 FY25 10-Q highlights
- Revenue collapsed to $0.25 m (Q2 24: $1.07 m; 1H 24: $53.5 m, benefited from a $40 m Roche milestone now absent).
- Expense discipline: R&D cut 53 % and G&A down 28 %, driving total operating costs to $23.7 m (-38 % YoY). Restructuring charges of $3.4 m reflect a workforce reduction of ~75 % by Q4 25.
- Earnings: Net loss narrowed to $16.7 m (-$0.39/sh) from $34.8 m; 1H loss $46.8 m.
- Liquidity: Cash & marketable securities of $109.5 m; management guides funding runway to 2027.
- Strategic monetisation: Out-licensed discovery platforms to DCx ( $1 m cash, $3 m receivable, 9.99 % equity, $5.7 m gain booked ). Post-quarter, licensed lunresertib to Debiopharm for $10 m upfront plus up to $257 m milestones and single-digit royalties.
- Pipeline focus: resources concentrated on Phase 1 programs RP-3467 (POLAR) and RP-1664 (LIONS); topline safety/efficacy data expected Q4 25.
- Other: Bristol-Myers Squibb paid a $0.25 m option fee for an additional druggable target.
Cost reductions and asset deals offset revenue loss, but future value hinges on early-stage clinical read-outs.
Repare Therapeutics Inc. (Nasdaq: RPTX) filed a Form 8-K to disclose changes approved by its Compensation Committee on June 13, 2025 to the severance package of Michael Zinda, Ph.D., Executive Vice President & Chief Scientific Officer.
Under the amended terms, if Dr. Zinda is terminated without “cause” or resigns for “good reason,” and the separation is not in connection with a change-in-control, he will receive:
- Lump-sum cash equal to nine months of current base salary.
- COBRA premiums paid by Repare for up to 12 months post-separation.
- Accelerated vesting of all unvested equity awards for nine months from the separation date.
- Pro-rated target bonus for the year of separation, paid in a lump sum.
If a change in control occurs within 90 days after the separation date, Dr. Zinda will instead receive the enhanced change-in-control severance stipulated in Section 5.7(c) of his previously disclosed Employment Agreement. All other existing severance protections in that agreement remain unchanged.
The disclosure is limited to executive compensation; no financial results, operational updates, or strategic transactions were reported.
FAQ
What is the current stock price of Repare Therapeutics (RPTX)?
What is the market cap of Repare Therapeutics (RPTX)?
